Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TOBY ATLAS: A Multi-Site, Non-Interventional Study of Urinary Volatile Organic Compounds

NCT07933042 is registered in ClinicalTrials.gov with Toby, Inc. as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07933042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
TOBY ATLAS: A Multi-Site, Non-Interventional Study of Urinary Volatile Organic Compounds
Lead sponsor
Toby, Inc.
Phase
Observational
Overall status
Not yet recruiting
Start date
January 31, 2027
Completion date
January 31, 2032
Enrollment
30,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, cancer

Arms

As registered; 2 arms.

  • Target disease cases

    Participants with a target disease established by the applicable reference standard, including participants assessed after treatment where specified.

  • Controls

    Participants without the target disease for a given analysis, including healthy participants and participants with other diseases, benign conditions, or negative diagnostic work-ups.

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Clinical performance of each locked assay At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.

    Sensitivity and specificity at pre-specified thresholds, and area under the receiver operating characteristic curve, of each locked assay against the applicable reference standard in its intended-use population, using blinded validation specimens not used to develop that assay. Estimates will include 95% confidence intervals.

  • Paired comparison with available standard-of-care tests At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.

    Differences in sensitivity, specificity, and area under the receiver operating characteristic curve between each locked assay and each available standard-of-care test in the same participants, with 95% confidence intervals.

Similar trials

Same condition (Alzheimer Disease) and phase, most recent start first.